Cell Free DNA (cfDNA) Testing Market Report 2026

Cell Free DNA (cfDNA) Testing Market Overview

• Cell Free DNA (cfDNA) Testing market size has reached to $10.84 billion in 2025 • Expected to grow to $28.81 billion in 2030 at a compound annual growth rate (CAGR) of 21% • Growth Driver: Impact Of Rising Cancer Prevalence On The Cell-Free DNA (cfDNA) Testing Market • Market Trend: Labcorp Launches An Advanced Liquid Biopsy Test For Precision Oncology • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cell Free DNA (cfDNA) Testing Market?

Cell-free DNA (cfDNA) testing is a non-invasive diagnostic method that analyzes DNA fragments circulating freely in the bloodstream. cfDNA testing is utilized in liquid biopsy procedures and allows for detecting and analyzing genetic mutations and alterations without the need for a traditional tissue biopsy. The main products of the cell-free DNA (cfDNA) testing market are donor-derived cell-free DNA, circulating cell-free tumor DNA, and cell-free fetal DNA. Donor-derived cell-free DNA refers to cfDNA that comes from a transplanted donor organ or tissue and is present in the recipient's bloodstream. The various platforms include next-generation sequencing (NGS), rPCR and multiplex PCR, qPCR and dPCR, and other platforms, used for various applications such as oncology, NIPT (non-invasive prenatal test), gynecology, transplantation, and other disease conditions.

What Is The Cell Free DNA (cfDNA) Testing Market Growth Forecast?

The cell free dna (cfdna) testing market size is expected to see exponential growth in the next few years. It will grow to $28.81 billion in 2030 at a compound annual growth rate (CAGR) of 21.0%. The growth in the forecast period can be attributed to increasing investments in precision oncology, rising demand for early cancer detection, expansion of transplant monitoring applications, growing adoption of personalized medicine, increasing integration of AI-driven genomic analysis. Major trends in the forecast period include increasing adoption of liquid biopsy diagnostics, rising use of ngs-based cfdna analysis, growing demand for non-invasive prenatal testing, expansion of oncology monitoring applications, enhanced integration of bioinformatics platforms.

Global Cell Free DNA (cfDNA) Testing Market Segmentation

1) By Product: Donor-Derived Cell-Free DNA, Circulating Cell-Free Tumor DNA, Cell-Free Fetal DNA 2) By Platforms: Next Generation Sequencing (NGS), rPCR And Multiplexed PCR, qPCR And dPCR, Other platforms 3) By Application: Oncology, Non-Invasive Prenatal Test (NIPT), Gynecology, Transplantation, Other Applications Subsegments: 1) By Donor-Derived Cell-Free DNA: Organ Transplant Monitoring, Graft Rejection Detection 2) By Circulating Cell-Free Tumor DNA: Cancer Detection, Minimal Residual Disease Monitoring, Liquid Biopsy 3) By Cell-Free Fetal DNA: Non-Invasive Prenatal Testing (NIPT), Fetal Genetic Disorder Screening

What Is The Driver Of The Cell Free DNA (cfDNA) Testing Market?

The rising prevalence of cancer is expected to propel the growth of the cell-free DNA (cfDNA) testing market going forward. Cancer is a complex group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. These cells can invade and destroy normal tissue and, if not controlled, can significantly harm the body. The prevalence of cancer is due to aging populations, shifts in lifestyle, environmental influences, and advancements in detection and diagnostic techniques. cfDNA testing detects genetic mutations associated with cancer at an early stage, often before symptoms appear. This allows for early intervention, improving patient outcomes and survival rates by identifying cancer in its initial stages. For instance, in February 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, there are expected to be over 35 million new cases of cancer in 2050, a 77% increase over the projected 20 million cases in 2022. Therefore, the rising prevalence of cancer is driving the growth of the cell-free DNA (cfDNA) testing market.

Key Players In The Global Cell Free DNA (cfDNA) Testing Market

Major companies operating in the cell free dna (cfdna) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen N.V., Exact Sciences Corporation, Bio-Techne Corporation, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Invitae Corporation, Foundation Medicine Inc., Guardant Health Inc., Integrated DNA Technologies Inc., Caris Life Sciences Inc., Twist Bioscience Corporation, Adaptive Biotechnologies Corporation, Biodesix Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems Inc., Circulogene Theranostics LLC

Global Cell Free DNA (cfDNA) Testing Market Trends and Insights

Major companies operating in the cell-free DNA (cfDNA) testing market focus on developing innovative technologies, such as liquid biopsy tests that offer greater sensitivity, specificity, and efficiency in detecting cancer-related mutations and genetic alterations. Liquid biopsy tests refer to diagnostic procedures that allow oncologists to evaluate circulating cell-free DNA released by tumor cells, facilitating personalized, targeted therapy plans. For instance, in May 2023, Laboratory Corporation of America Holdings (Labcorp), a US-based life sciences company, launched Labcorp Plasma Focus, a new liquid biopsy test designed for patients with advanced or metastatic solid tumors. This test evaluates circulating cell-free DNA (cfDNA) released by tumor cells from a standard blood draw, making it minimally invasive and providing fast results. It enhances access to precision oncology by identifying clinically actionable biomarkers across several common cancers, such as non-small cell lung, colorectal, breast, esophageal, gastroesophageal junction, gastric cancers, and melanoma.

What Are Latest Mergers And Acquisitions In The Cell Free DNA (cfDNA) Testing Market?

In February 2024, Veracyte Inc., a US-based genomic diagnostics company, acquired C2i Genomics for an undisclosed amount. With this acquisition, Veracyte aims to expand its oncology testing capabilities, accelerate the development of precision oncology solutions, enhance its genomic insights for cancer care, and strengthen its overall diagnostic portfolio. C2i Genomics is a US-based healthcare technology company specializing in cell free DNA (cfDNA) testing.

Regional Outlook

North America was the largest region in the cell-free DNA (cfDNA) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cell Free DNA (cfDNA) Testing Market?

The cell-free DNA (cfDNA) testing market consists of revenue entities earned by providing services such as liquid biopsy for cancer detection and monitoring, transplant rejection monitoring, and non-invasive prenatal testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell-free DNA (cfDNA) testing market also includes sales of products such as digital PCR systems, automated nucleic acid extraction systems, real-time PCR instruments, and library preparation systems for NGS. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cell Free DNA (cfDNA) Testing Market Report 2026?

The cell free dna (cfdna) testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cell free dna (cfdna) testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.